AbbVie Inc. (ABBV)
NYSE: ABBVHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:02 PM ET · Delayed 15 min
ABBV stock chart
Technical analysisKey statistics
All statistics- Market cap
- $505.89B
- P/E (TTM)
- 49.18
- Forward P/E
- 17.65
- EPS (TTM)
- $5.82
- Dividend yield
- 2.42% ($6.92)
- Ex-dividend date
- Oct 15, 2026
- 52-week range
- 190.75 – 302.93
- Day range
- 284.85 – 290.23
- Volume / Avg
- 8.76M / 4.84M
- Beta
- —
- Shares outstanding
- 1.77B
52-week range
ABBV stock today
Shares of AbbVie (ABBV) finished higher on Nov 20 at $286.20, a gain of 0.94% or $2.66 per share, versus the S&P 500's 3.70% decline. Shares are 5.5% below their 52-week high of $302.93, set on Nov 5, 2026 and 50.0% above the 52-week low of $190.75, near the top of the past year's range. ABBV is up 25.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 21.1%.
At 49.2x trailing earnings, AbbVie trades above the peer-group median of 35.8x. Its forward P/E of 17.6x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. AbbVie pays an annual dividend of $6.92 per share, a 2.42% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About AbbVie
Company profileAbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Robert A. Michael CPA
- Headquarters
- North Chicago, IL
- Employees
- 57,000
- IPO year
- 2012
- Website
- abbvie.com
Financial highlights
Full financialsIn fiscal 2025, AbbVie generated $61.16 billion in revenue, up 8.6% from fiscal 2024, its 2nd consecutive year of revenue growth. Net income was $4.23 billion (-1.2% year over year), for a net margin of 6.9% versus a median of 10.1% in the prior 5 years. Gross margin was 70.2% (up from 70.0%) and operating margin 24.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $61.16B | $56.33B | $54.32B | $58.05B | $56.20B |
| Growth | +8.57% | +3.71% | -6.44% | +3.30% | +22.69% |
| Net income | $4.23B | $4.28B | $4.86B | $11.84B | $11.54B |
| EPS (diluted) | $2.36 | $2.39 | $2.72 | $6.63 | $6.45 |
Analyst forecast
ForecastConsensus (29 analysts)
buy
Avg. price target
$314.12+9.76%
- Strong buy 7
- Buy 16
- Hold 5
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 30, 2026
- EPS actual vs est.
- $1.86 vs $3.74
- Surprise
- -50.27%
Dividends
Dividend history- Annual dividend
- $6.92
- Dividend yield
- 2.42%
- Last payment
- $1.73
- Ex-dividend date
- Oct 15, 2026
ABBV news
All ABBV news- AbbVie (ABBV) Stock Just Got a 5.2% Dividend Increase. Here's How Many Shares You Need to Generate $1,000 a Year.Nasdaq
- AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy for 2027?NasdaqABBV, LLY
- Weekly Buzz: SNY, REGN Score Approvals; MIST Cuts Costs; ABBV, LLY, JNJ Strike DealsNasdaqABBV, BIIB, BMY, ENLV
- AbbVie to Present at the Piper Sandler 38th Annual Healthcare ConferencePR Newswire
- PFE Inks $2.6B Licensing Deal With Chinese Biotech for CAR-T TherapiesNasdaqPFE, LLY, ABBV
- Is Immunology Emerging as Eli Lilly's Next Growth Driver?NasdaqLLY, NVS, JNJ, ABBV
- ProKidney Names Farah Ali CMO As Phase 3 Kidney Therapy Trial AdvancesNasdaqABBV, AMGN, IMVT, PROK
- AbbVie, DISCO Partner On Solid Tumor Therapies; Deal Includes Up To $2.5 Bln In MilestonesNasdaqABBV, BF.A
AbbVie peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| JNJJohnson & Johnson | 270.47 | +1.25% | $651.11B | vs ABBV |
| MRKMerck & Company Inc. | 133.72 | +0.69% | $329.65B | vs ABBV |
| NVSNovartis AG | 150.47 | -0.50% | $284.18B | vs ABBV |
| AZNAstraZeneca PLC | 174.35 | -0.60% | $270.40B | vs ABBV |
| ABTAbbott Laboratories | 103.00 | -0.84% | $178.39B | vs ABBV |
| NVONovo Nordisk A/S | 37.82 | -2.70% | $166.69B | vs ABBV |
| PFEPfizer Inc. | 27.40 | -0.51% | $156.18B | vs ABBV |
| VRTXVertex Pharmaceuticals Incorporated | 515.02 | -1.08% | $130.58B | vs ABBV |
Indexes, lists and sector
Index membership
Appears in lists
AbbVie stock FAQ
What is AbbVie's stock price today?
ABBV last traded at $286.20 as of Nov 20, 4:02 PM EST, up 0.94% on the day. Prices are delayed at least 15 minutes.
Does AbbVie pay a dividend?
Yes. AbbVie pays $6.92 per share annually, a 2.42% yield. The most recent dividend of $1.73 had an ex-dividend date of Oct 15, 2026.
What is ABBV's P/E ratio?
ABBV trades at a trailing P/E ratio of 49.18 and a forward P/E of 17.65, compared with a median of 35.8 for its closest peers.
Is AbbVie in the S&P 500?
Yes. AbbVie (ABBV) is a constituent of the S&P 500 index.
Who is AbbVie's CEO?
Mr. Robert A. Michael CPA is the chief executive officer of AbbVie Inc., which has about 57,000 employees.
What is the ABBV 52-week high?
The 52-week high for ABBV is $302.93 and the 52-week low is $190.75. The stock is currently 5.5% below its high.